126 related articles for article (PubMed ID: 20701970)
21. Proposal for revised diagnostic criteria of essential thrombocythemia and polycythemia vera by the Thrombocythemia Vera Study Group.
Michiels JJ; Juvonen E
Semin Thromb Hemost; 1997; 23(4):339-47. PubMed ID: 9263350
[TBL] [Abstract][Full Text] [Related]
22. Plasma basic fibroblast growth factor and bone marrow fibrosis in clonal myeloproliferative disorders.
Sayinalp N; Cinar H; Uner A; Haznedaroğlu IC; Büyükaşik Y; Göker H; Aksu S; Ozcebe OI; Karakuş S; Kirazli S; Dündar SV
Clin Lab Haematol; 2004 Aug; 26(4):265-8. PubMed ID: 15279663
[TBL] [Abstract][Full Text] [Related]
23. Myelofibrosis in myeloproliferative disorders.
Srinivasan U; Talvalkar GV; Advani SH
Indian J Cancer; 1978 Sep; 15(3):37-43. PubMed ID: 294411
[No Abstract] [Full Text] [Related]
24. Myelofibrosis in the myeloproliferative disorders.
Ellis JT; Peterson P
Prog Clin Biol Res; 1984; 154():19-42. PubMed ID: 6382293
[TBL] [Abstract][Full Text] [Related]
25. Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres.
Kuter DJ; Bain B; Mufti G; Bagg A; Hasserjian RP
Br J Haematol; 2007 Nov; 139(3):351-62. PubMed ID: 17910625
[TBL] [Abstract][Full Text] [Related]
26. [Emperipolesis in megakaryocytes in patients with thrombocytosis in the course of myeloproliferative disorders].
Bobik R; Podolak-Dawidziak M; Kiełbiński M; Jeleń M; Wróbel T
Acta Haematol Pol; 1995; 26(2):179-83. PubMed ID: 7653223
[TBL] [Abstract][Full Text] [Related]
27. [Bone marrow fibrosis in malignant hemopathies and cancers. Histological study of 2 786 biopsies (author's transl)].
Duhamel G; Stachowiak J
Sem Hop; 1981 Jan 18-25; 57(3-4):111-6. PubMed ID: 6261348
[TBL] [Abstract][Full Text] [Related]
28. Clinicopathological impact of the interaction between megakaryocytes and myeloid stroma in chronic myeloproliferative disorders: a concise update.
Thiele J; Kvasnicka HM; Fischer R; Diehl V
Leuk Lymphoma; 1997 Feb; 24(5-6):463-81. PubMed ID: 9086437
[TBL] [Abstract][Full Text] [Related]
29. Platelet-derived growth factor receptor β (PDGFRβ) immunohistochemistry highlights activated bone marrow stroma and is potentially predictive for fibrosis progression in prefibrotic myeloproliferative neoplasia.
Méhes G; Tzankov A; Hebeda K; Anagnostopoulos I; Krenács L; Bedekovics J
Histopathology; 2015 Nov; 67(5):617-24. PubMed ID: 25825163
[TBL] [Abstract][Full Text] [Related]
30. [Pulmonary hypertension in chronic myeloproliferative disorders].
Einsfelder BM; Müller KM
Pathologe; 2005 May; 26(3):169-77. PubMed ID: 15257414
[TBL] [Abstract][Full Text] [Related]
31. Tetraspanin CD9 participates in dysmegakaryopoiesis and stromal interactions in primary myelofibrosis.
Desterke C; Martinaud C; Guerton B; Pieri L; Bogani C; Clay D; Torossian F; Lataillade JJ; Hasselbach HC; Gisslinger H; Demory JL; Dupriez B; Boucheix C; Rubinstein E; Amsellem S; Vannucchi AM; Le Bousse-Kerdilès MC
Haematologica; 2015 Jun; 100(6):757-67. PubMed ID: 25840601
[TBL] [Abstract][Full Text] [Related]
32. Quantitative analysis of growth factor production in the mechanism of fibrosis in agnogenic myeloid metaplasia.
Wang JC; Chang TH; Goldberg A; Novetsky AD; Lichter S; Lipton J
Exp Hematol; 2006 Dec; 34(12):1617-23. PubMed ID: 17157157
[TBL] [Abstract][Full Text] [Related]
33. Myelofibrosis revisited: characterization and classification of myelofibrosis in the setting of myeloproliferative disease.
Gilbert HS
Prog Clin Biol Res; 1984; 154():3-17. PubMed ID: 6382299
[TBL] [Abstract][Full Text] [Related]
34. Aberrant expression of transforming growth factor beta-1 (TGF beta-1) per se does not discriminate fibrotic from non-fibrotic chronic myeloproliferative disorders.
Bock O; Loch G; Schade U; von Wasielewski R; Schlué J; Kreipe H
J Pathol; 2005 Apr; 205(5):548-57. PubMed ID: 15726648
[TBL] [Abstract][Full Text] [Related]
35. [Incidence of mononuclear bone-marrow megakaryocytes in various hemopathies].
Simón R; Woessner S
Sangre (Barc); 1988 Jun; 33(3):238-9. PubMed ID: 3175821
[No Abstract] [Full Text] [Related]
36. Chronic myeloproliferative disorders: the bone marrow stromal component is not involved in the malignant clone.
Di Ianni M; Moretti L; Del Papa B; De Ioanni M; Bonifacio E; Falzetti F; Tabilio A
Leukemia; 2007 Feb; 21(2):377-8. PubMed ID: 17251905
[No Abstract] [Full Text] [Related]
37. Bone marrow biopsy (BMB). II. Bone marrow biopsy in myeloproliferative disorders.
Macavei I; Galatâr N
Morphol Embryol (Bucur); 1989; 35(2):117-27. PubMed ID: 2529429
[TBL] [Abstract][Full Text] [Related]
38. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases.
Orazi A
Pathobiology; 2007; 74(2):97-114. PubMed ID: 17587881
[TBL] [Abstract][Full Text] [Related]
39. [So-called primary (idiopathic) osteomyelofibrosis/-sclerosis (OMF) within the scope of chronic myeloproliferative diseases. I. Initial clinical and histologic findings in 102 patients with special reference to early hyperplastic and advanced fibrosclerotic stages].
Zankovich R; Thiele J; Mödder B; Steinberg T; Simon KG; Fischer R; Diehl V
Med Klin (Munich); 1988 Oct; 83(19):617-28. PubMed ID: 3185420
[No Abstract] [Full Text] [Related]
40. [Diagnosis of chronic myeloproliferative diseases based on bone marrow biopsy].
Matolcsy A; Kónya T; Wéber E
Orv Hetil; 1992 Jun; 133(26):1617-20, 1625-6. PubMed ID: 1614699
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
